Technology | 2019.10.03
Asymmetrex Leads OCTNE 2019 Discussion of the Growing Need for Tissue Stem Cell-Specific Dosing In Stem Cell Clinical Trials
As the field of stem cell medicine begins to wake up to its critical need for tissue stem cell-specific dosing, biotechnology tools company Asymmetrex is leading the way. This week in Boston, at the 2019 Outsourcing in Clinical Trials New England conference, the company’s director gave a pointed presentation on how the current lack of stem cell-specific dosing is now unnecessarily undermining the quality of stem cell clinical trials as well as even approved stem cell treatments. Though not the focus of the presentation, Asymmetrex developed the first, and currently the only, technology for specific counting of therapeutic tissue stem cells.
(PRWeb October 03, 2019)
Read the full story at https://www.prweb.com/releases/asymmetrex_leads_octne_2019_discussion_of_the_growing_need_for_tissue_stem_cell_specific_dosing_in_stem_cell_clinical_trials/prweb16621594.htm
For more information, please visit
https://www.prweb.com/releases/asymmetre[...]nical_trials/prweb16621594.htm
Instagram is adding automatic in-app text translation - The Verge views: 1567
Instagram is adding automatic in-app text translation - The Verge views: 1507